NO961151D0 - Antistoffer mot CD40 - Google Patents

Antistoffer mot CD40

Info

Publication number
NO961151D0
NO961151D0 NO961151A NO961151A NO961151D0 NO 961151 D0 NO961151 D0 NO 961151D0 NO 961151 A NO961151 A NO 961151A NO 961151 A NO961151 A NO 961151A NO 961151 D0 NO961151 D0 NO 961151D0
Authority
NO
Norway
Prior art keywords
antibodies
binding
ligand
monoclonal antibodies
specifically bind
Prior art date
Application number
NO961151A
Other languages
English (en)
Norwegian (no)
Other versions
NO961151L (no
Inventor
Iii William C Fanslow
Jodee Zappone
Mark Alderson
Richard J Armitage
Original Assignee
Immunex Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunex Corp filed Critical Immunex Corp
Publication of NO961151L publication Critical patent/NO961151L/no
Publication of NO961151D0 publication Critical patent/NO961151D0/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
NO961151A 1993-10-01 1996-03-21 Antistoffer mot CD40 NO961151D0 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13054193A 1993-10-01 1993-10-01
PCT/US1994/009984 WO1995009653A1 (fr) 1993-10-01 1994-09-02 Anticorps diriges contre le cd40

Publications (2)

Publication Number Publication Date
NO961151L NO961151L (no) 1996-03-21
NO961151D0 true NO961151D0 (no) 1996-03-21

Family

ID=22445171

Family Applications (1)

Application Number Title Priority Date Filing Date
NO961151A NO961151D0 (no) 1993-10-01 1996-03-21 Antistoffer mot CD40

Country Status (15)

Country Link
US (1) US5801227A (fr)
EP (1) EP0724456B1 (fr)
JP (1) JP3675819B2 (fr)
KR (1) KR960704576A (fr)
AT (1) ATE255906T1 (fr)
AU (1) AU686230B2 (fr)
CA (1) CA2172376C (fr)
DE (1) DE69433406T2 (fr)
DK (1) DK0724456T3 (fr)
ES (1) ES2211884T3 (fr)
FI (1) FI961285A7 (fr)
NO (1) NO961151D0 (fr)
NZ (1) NZ273504A (fr)
PT (1) PT724456E (fr)
WO (1) WO1995009653A1 (fr)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5874082A (en) * 1992-07-09 1999-02-23 Chiron Corporation Humanized anti-CD40 monoclonal antibodies and fragments capable of blocking B cell proliferation
US5397703A (en) * 1992-07-09 1995-03-14 Cetus Oncology Corporation Method for generation of antibodies to cell surface molecules
AU699291B2 (en) * 1995-03-01 1998-11-26 Immunex Corporation Method for stimulating an immune response
US6340459B1 (en) 1995-12-01 2002-01-22 The Trustees Of Columbia University In The City Of New York Therapeutic applications for the anti-T-BAM (CD40-L) monoclonal antibody 5C8 in the treatment of reperfusion injury in non-transplant recipients
US20020102706A1 (en) * 1997-06-18 2002-08-01 Genentech, Inc. Apo-2DcR
JP2002508663A (ja) * 1997-06-18 2002-03-19 ジェネンテク，インコーポレイテッド Ａｐｏ−２ＤｃＲ
ES2330017T3 (es) * 1998-05-23 2009-12-03 Leiden University Medical Center Ligandos de cd40 y peptidos de ctl para tratar tumores.
EP2039368A3 (fr) 1999-04-30 2009-04-01 La Jolla Institute For Allergy And Immunology Procédé pour empêcher la réactivation d'un virus latent et contrôler la réplication du virus
US6946129B1 (en) 1999-06-08 2005-09-20 Seattle Genetics, Inc. Recombinant anti-CD40 antibody and uses thereof
DE60035057T2 (de) * 1999-10-04 2008-01-31 Novartis Vaccines and Diagnostics, Inc., Emeryville CD40 Antagonist zur Behandlung von Psoriasis
US20020028178A1 (en) * 2000-07-12 2002-03-07 Nabil Hanna Treatment of B cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications
AU2001236621B2 (en) 2000-02-01 2006-06-15 Mycenax Biotech Inc. Cd40-binding apc-activating molecules
EP1286692A4 (fr) * 2000-04-25 2004-11-17 Idec Pharma Corp Administration intrathecale de rituximab pour le traitement des lymphomes du systeme nerveux central
US20030059427A1 (en) * 2000-04-28 2003-03-27 Force Walker R. Isolation and characterization of highly active anti-CD40 antibody
US7063845B2 (en) 2000-04-28 2006-06-20 Gemini Science, Inc. Human anti-CD40 antibodies
AU2001259215A1 (en) * 2000-04-28 2001-11-12 La Jolla Institute For Allergy And Immunology Human anti-cd40 antibodies and methods of making and using same
WO2002028905A2 (fr) 2000-10-02 2002-04-11 Chiron Corporation Anticorps humains anti-cd40
US20070065436A1 (en) * 2001-01-31 2007-03-22 Biogen Idec Inc. Anti-cd80 antibody having adcc activity for adcc mediated killing of b cell lymphoma cells alone or in combination with other therapies
US20030103971A1 (en) * 2001-11-09 2003-06-05 Kandasamy Hariharan Immunoregulatory antibodies and uses thereof
CN100574803C (zh) 2001-01-31 2009-12-30 拜奥根Idec公司 免疫调节抗体在治疗肿瘤性疾病中的用途
US20030211107A1 (en) * 2002-01-31 2003-11-13 Kandasamy Hariharan Use of CD23 antagonists for the treatment of neoplastic disorders
US20020159996A1 (en) 2001-01-31 2002-10-31 Kandasamy Hariharan Use of CD23 antagonists for the treatment of neoplastic disorders
EP2011802A3 (fr) * 2001-04-27 2009-04-15 Kyowa Hakko Kirin Co., Ltd. Anticorps monoclonal anti-CD40
CA2492823A1 (fr) * 2001-09-14 2003-03-27 Cytos Biotechnology Ag Activation in vivo de cellules presentant un antigene en vue d'augmenter les reponses immunes induites par des particules de type virus
AR039067A1 (es) 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
US20050069549A1 (en) 2002-01-14 2005-03-31 William Herman Targeted ligands
US20030180292A1 (en) * 2002-03-14 2003-09-25 Idec Pharmaceuticals Treatment of B cell malignancies using anti-CD40L antibodies in combination with anti-CD20 antibodies and/or chemotherapeutics and radiotherapy
US8277810B2 (en) 2003-11-04 2012-10-02 Novartis Vaccines & Diagnostics, Inc. Antagonist anti-CD40 antibodies
SI1680141T1 (sl) * 2003-11-04 2010-12-31 Novartis Vaccines & Diagnostic Postopki terapije za trdne tumorje, ki izražajo CD-40 celično-površinski antigen
US20050136055A1 (en) * 2003-12-22 2005-06-23 Pfizer Inc CD40 antibody formulation and methods
BRPI0509201A (pt) 2004-03-23 2007-08-28 Biogen Idec Inc agentes de acoplamento de receptor e usos terapêuticos destes
US20080057070A1 (en) * 2004-11-04 2008-03-06 Chiron Corporation Antagonist Anti-Cd40 Monoclonal Antibodies and Methods for Their Use
JP2009517339A (ja) * 2005-11-01 2009-04-30 ノバルティス アーゲー 抗ｃｄ４０抗体の使用
JP2009513712A (ja) * 2005-11-01 2009-04-02 ノバルティス アーゲー 抗ｃｄ４０抗体の使用
GEP20125628B (en) 2006-04-21 2012-09-10 Novartis Ag Pharmaceutical compositions containing antagonist anti-cd40 antibody
EP2589654A1 (fr) 2006-05-03 2013-05-08 The Regents of the University of Colorado, a body corporate Combinaison 'anticorps agoniste CD40/adjuvant synergique d'interféron de type 1, conjugués la contenant et son utilisation comme agent thérapeutique pour améliorer l'immunité cellulaire
US20090074711A1 (en) * 2006-09-07 2009-03-19 University Of Southhampton Human therapies using chimeric agonistic anti-human cd40 antibody
AR083847A1 (es) 2010-11-15 2013-03-27 Novartis Ag Variantes de fc (fragmento constante) silenciosas de los anticuerpos anti-cd40
PT2683406T (pt) 2011-03-11 2019-07-08 Beth Israel Deaconess Medical Ct Inc Anticorpos anti-cd40 e utilização dos mesmos
ES2709654T3 (es) 2011-04-29 2019-04-17 Apexigen Inc Anticuerpos anti-CD40 y métodos de uso
CN104918957B (zh) 2012-10-30 2018-11-16 埃派斯进有限公司 抗-cd40抗体及其使用方法
RU2715597C2 (ru) 2015-05-29 2020-03-02 Эббви Инк. Антитела к cd40 и способы их применения
HUE056769T2 (hu) 2015-09-04 2022-03-28 Primatope Therapeutics Inc Humanizált anti-CD40 antitestek és felhasználásuk
BR112018006360A2 (pt) 2015-09-30 2018-10-09 Janssen Biotech Inc anticorpos agonísticos que se ligam especificamente ao cd40 humano e métodos de uso
ES3041500T3 (en) 2016-03-10 2025-11-12 Cg Oncology Inc Methods of treating solid tumors by combination therapy
JP7038064B2 (ja) 2016-04-18 2022-03-17 セルデックス セラピューティクス インコーポレイテッド ヒトｃｄ４０に結合するアゴニスト抗体およびその使用
JP7461741B2 (ja) 2016-06-20 2024-04-04 カイマブ・リミテッド 抗ｐｄ－ｌ１およびｉｌ－２サイトカイン
WO2018088850A2 (fr) * 2016-11-11 2018-05-17 다이노나(주) Anticorps se liant spécifiquement à cd40 et utilisations associée
EP4393937A4 (fr) 2021-08-26 2025-12-31 Duality Biologics Shanghai Co Ltd Composé stéroïde et conjugué de celui-ci
US12234294B2 (en) 2021-11-05 2025-02-25 Kiniksa Pharmaceuticals, Gmbh Pharmaceutical composition of a humanized anti-CD40 antibody
WO2025186778A1 (fr) 2024-03-08 2025-09-12 Janssen Biotech, Inc. Combinaisons de virus oncolytiques et d'immunomodulateurs

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5247069A (en) * 1986-06-13 1993-09-21 Oncogen Ligands and methods for augmenting B-cell proliferation
US5397703A (en) * 1992-07-09 1995-03-14 Cetus Oncology Corporation Method for generation of antibodies to cell surface molecules

Also Published As

Publication number Publication date
DE69433406D1 (de) 2004-01-22
NO961151L (no) 1996-03-21
EP0724456A1 (fr) 1996-08-07
CA2172376A1 (fr) 1995-04-13
PT724456E (pt) 2004-04-30
JP3675819B2 (ja) 2005-07-27
FI961285A0 (fi) 1996-03-20
FI961285L (fi) 1996-03-20
KR960704576A (ko) 1996-10-09
ATE255906T1 (de) 2003-12-15
WO1995009653A1 (fr) 1995-04-13
FI961285A7 (fi) 1996-03-20
JPH09504169A (ja) 1997-04-28
DK0724456T3 (da) 2004-04-13
ES2211884T3 (es) 2004-07-16
AU7681994A (en) 1995-05-01
EP0724456A4 (fr) 1997-07-02
AU686230B2 (en) 1998-02-05
EP0724456B1 (fr) 2003-12-10
NZ273504A (en) 1997-12-19
CA2172376C (fr) 2008-11-18
US5801227A (en) 1998-09-01
DE69433406T2 (de) 2004-10-07

Similar Documents

Publication Publication Date Title
FI961285A0 (fi) CD40:n vasta-aineita
DE69429925D1 (de) METHODE ZUR BINDUNG VON MATERIAL AN DAS Beta-AMYLOID-PEPTID
ES2106195T3 (es) Anticuerpo igg aglicosilado anti cd3.
NO963097D0 (no) Humaniserte antistoffer mot leukocytt-adhesjonsmolekyl VLA-4
DE69233735D1 (de) Bindungsdomänen des Delta-proteins
CA2064915A1 (fr) Ligands de fixation du facteur de necrose tumorale
DE69531679D1 (de) Für e-selectin und p-selectin spezifische kreuzreaktive monoklonale antikörper
ZA946767B (en) Monocional antibodies having property of causing apoptosis.
DE68914244D1 (de) Monoklonaler Antikörper.
NO20010747D0 (no) Antitrombotisk middel og humanisert anti-von Willebrand faktor monoklonalt antistoff
DK0812206T3 (da) Fremgangsmåde til stimulering af en immunrespons
FI945865A7 (fi) Glykoprofeiini P:lle kohdistettuja monoklonaalisia vasta-aineita
DE69535855D1 (de) Calciumbindende rekombinante antikörper gegen protein c
DE3586216D1 (de) Brusttumorassoziiertes antigen und monoklonale antikoerper dazu.
NO890116L (no) Monoklonale antistoffer.
FI893928A7 (fi) Monoklonala motkroppar.
AU6068000A (en) Peptide ligands that bind igm antibodies and block interaction with antigen
ITRM920223A0 (it) Anticorpi monoclonali anti-idiopici diretti contro anticorpi anti-tnf.
DE69020315D1 (de) Monoklonaler antikörper gegen c-reaktives protein.
NO903788D0 (no) Monoklonalt antistoff mot protein c.
NO911300D0 (no) Homoklonale antistoffer mot reseptor-fremkalte bindingsseter.
ATA98792A (de) Peptide, die antikörper binden
HUP0003029A2 (hu) Ankrod specifikus monoklonális antitestek, antitestfragmentumok, keverékeik és alkalmazásuk
GB2333295A (en) Modified protein G and fragments thereof
DE69324928D1 (de) Monoklonaler antikörper

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application